To elaborate, SSc patients are characterized by an increased naïve (CD19+CD27-) and a reduced activated memory B (CD19+CD27+) cell phenotype that is accompanied by overexpressed pro-apoptotic and activation markers such as CD95, CD86, and human leukocyte antigen-DR isotype (HLA-DR) [4,85,86,87,88]. The gene discussed is CD19; the disease is systemic sclerosis.